APT Pharmaceuticals Adds On $22M

Burlingame, California-based APT Pharmaceuticals said Thursday that it has raised an additional $22M in funding, in a Series A-2 round. The new funding came from Versant Ventures and Great Point Partners, along with existing investors Vivo Ventures and Charter Life Sciences. Camille Samuels of Versant and David Kroin of Great Point have joined the firm's board as part of the funding. APT is developing treatments to prevent lung transplant rejection, along with other compounds. The new round brings the company's total raise to more than $30M. More information »